Product Overview
[Drug Name]
Generic Name: Pantoprazole Sodium Enteric-Coated Tablets
Trade Name: Yifan Pantoprazole Sodium Enteric-Coated Tablets, 40mg x 7 tablets
Pinyin Full Code: ZuoTuoLaZuoNaChangRongPian
[Main Ingredient]
The main ingredient of this product is hemitoprazole sodium. Chemical Name: 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methyl]-sulfinyl}-1H-benzimidazole sodium monohydrate. Molecular Formula:
C₁₆H₁₄F₂N₃NaO₄S₆H₂O. Molecular Weight: 423.38
[Properties]
This product is an enteric-coated tablet. After removing the coating, it appears white or off-white.
[Indications/Main Functions]
It is indicated for active peptic ulcers (gastric and duodenal ulcers), reflux esophagitis, and Zollinger-Ellison syndrome.
[Specifications]
40mg*7 tablets
[Dosage and Administration]
Take 40mg (1 tablet) orally daily before breakfast. The treatment course for duodenal ulcers is usually 2-4 weeks, and for gastric ulcers and reflux esophagitis, it is usually 4-8 weeks.
[Adverse Reactions]
Dizziness, insomnia, drowsiness, nausea, diarrhea and constipation, rash, and muscle pain may occur with clinical use.
[Contraindications]
This product is contraindicated in patients with allergies, breastfeeding women, and women in the first trimester of pregnancy.
[Drug Interactions]
Oxytoprazole has minimal interactions with other drugs. Compared with omeprazole, it has less effect on the cytochrome P450 system and does not affect the duration of diazepam action. It has no significant interactions with oral contraceptives, digoxin, warfarin, phenytoin, or theophylline.
[Precautions]
1. High doses may cause arrhythmia, elevated transaminases, changes in renal function, and decreased granulocyte counts. 2. This product is an enteric-coated formulation. Do not chew when taking. 3. When gastric ulcers are suspected, cancer should be ruled out first. This is because treatment with this product may alleviate symptoms and delay diagnosis. 4. Efficacy and safety data for this product in children have not been established. 5. Use with caution in patients with hepatic and renal impairment.
[Pediatric Use]
Efficacy and safety data for this product in children have not been established. It is contraindicated in infants and young children.
[Elderly Use]
No dose adjustment is required.
[Overdose]
High doses may cause arrhythmia, elevated transaminases, changes in renal function, and granulocytopenia.
[Pharmacology and Toxicology]
This product inhibits gastric acid secretion by specifically targeting gastric mucosal parietal cells, reducing the activity of H+-K+-ATPase in these cells. Compared to omeprazole, this product has a weaker inhibitory effect on cytochrome P450 enzymes.
